New Antibody Test for Breast Cancer
Author Information
Author(s): Bussolati G, Montemurro F, Righi L, Donadio M, Aglietta M, Sapino A
Primary Institution: University of Turin, Torino, Italy
Hypothesis
Can a modified Trastuzumab antibody improve the detection of HER-2 overexpression in breast cancer?
Conclusion
The modified Trastuzumab antibody, BiotHER, can accurately detect HER-2 overexpression and predict clinical outcomes in breast cancer patients treated with Trastuzumab.
Supporting Evidence
- BiotHER staining was detected in 50% of tumours with HER-2 amplification.
- BiotHER positivity was independently associated with increased likelihood of tumour response.
- The combination of chemotherapy plus Trastuzumab produced a 74% response rate.
Takeaway
Researchers created a new test using a special antibody to help find breast cancer patients who can benefit from a specific treatment.
Methodology
The study involved modifying Trastuzumab to create BiotHER, which was tested on breast cancer samples to assess its ability to detect HER-2 overexpression and predict treatment outcomes.
Potential Biases
Potential bias due to retrospective analysis and variability in tissue processing methods.
Limitations
The study had a small sample size and results should be confirmed in larger trials.
Participant Demographics
54 women with HER-2 amplified advanced breast cancer, median age 55 years.
Statistical Information
P-Value
0.03
Confidence Interval
95% CI 61–84%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website